Passive antibody therapies: Progress and continuing challenges
Passive antibody therapies: Progress and continuing challenges
复制标题
DOI：
10.1006/clim.1999.4768
复制
发表时间：
1999-10-01
影响因子：
8.6
通讯作者：
Casadevall, A
中科院分区：
文献类型：
--
作者：
Casadevall, A
近年来，基于抗体的疗法已重新成为治疗各种不同疾病的一线疗法，包括病毒感染、炎症性疾病和某些恶性肿瘤。抗体生产技术的重大进步和对新的治疗剂的需求使人们对基于抗体的治疗重新产生了兴趣。数十种抗体制剂正在临床上使用。几种单抗现已获准临床使用，其中许多正处于高级临床开发阶段。与传统化疗相比，基于抗体的治疗既有显著的优势，也有明显的劣势。优势包括多功能性、特异性和生物学功能，这是现有化疗药物无法复制的。劣势包括成本高和市场小，这阻碍了商业发展。现有的经验表明，基于抗体的疗法可以成功地开发出来，用于没有有效疗法的临床情况。在基于抗体的疗法的发展中继续取得成功将需要广泛的临床研究，以了解如何最佳地使用这些化合物，并需要基础免疫学研究，以确定抗体作用的基本机制。(C)1999年学术出版社。
In recent years antibody-based therapies have returned as first-line therapy for a variety of diverse conditions that include viral infections, inflammatory disorders, and certain malignancies. Renewed interest in antibody-based therapies is a consequence of major advances in the technology of antibody production and the need for new therapeutic agents. Dozens of antibody preparations are in clinical use. Several monoclonal antibodies are now licensed for clinical use and many are in advanced clinical development. Antibody-based therapies have both significant advantages and disadvantages relative to conventional chemotherapy. Advantages include versatility, specificity, and biological functions not replicated by available chemotherapeutic drugs. Disadvantages include high cost and small markets that hinder commercial development. The available experience suggests that antibody-based therapies can be successfully developed for use in clinical situations where no effective therapy is available. Continued success in the development of antibody-based therapies will require extensive clinical research to learn how to use these compounds optimally and basic immunological research to define the basic mechanisms of antibody action. (C) 1999 Academic Press.